Ferraz-Amaro et al. showed that RA patients had lower PCSK9 levels than healthy controls, after adjustment for classical CVD risk factors, lipids and statins; this was attributed to the “lipid paradox” seen in patients with RA (25, 26). The gene discussed is PCSK9; the disease is rheumatoid arthritis.